Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Molecular Targets For Therapy (MTT)
  • Published:

Molecular Targets for Therapy (MTT)

Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

Leukemia volume 18, pages 1200–1206 (2004)Cite this article

Abstract

Mantle cell lymphoma (MCL) is a malignant lymphoma associated with a relatively aggressive clinical course and a median overall survival time of 3–4 years. Treatment usually consists of combination chemotherapy, often including topoisomerase (topo) inhibitors such as doxorubicin, etoposide and mitoxantrone. Topo IIα is an enzyme that is needed whenever uncoiling of DNA is necessary during the cell cycle. The enzyme is a marker of cell proliferation. We analyzed the expression of topo IIα in relation to Ki-67 and the clinical outcome in patients with MCL. Biopsy specimens from 95 untreated patients enrolled in two multicenter trials (1975–1985) were investigated immunohistochemically with monoclonal antibodies against topo IIα (Ki-S4) and Ki-67 (Ki-S5). Patients with low (0–10%) topo IIα expression had a median overall survival time of 49.0 months, compared to 17.0 months for patients with high (more than 10%) topo IIα expression. The Kaplan–Meier analysis showed a significant difference in the overall survival time related to the percentage of topo IIα (P<0.001) and Ki-67 (P<0.001) positive tumor cells. Multivariate Cox regression analysis revealed the expression of topo IIα as the most important prognostic factor (P<0.001) in MCL superior to the international prognostic index (IPI), the Ki-67 index and other clinical characteristics.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

References

  1. Lennert K, Stein H, Kaiserling E . Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975; 31 (Suppl): 29–43.

    Google Scholar 

  2. Tolksdorf G, Stein H, Lennert K . Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes). Br J Cancer 1980; 41: 168–182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM . Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984; 224: 1403–1406.

    Article  CAS  PubMed  Google Scholar 

  4. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197.

    Article  CAS  PubMed  Google Scholar 

  5. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710–1715.

    CAS  PubMed  Google Scholar 

  6. Gerdes J, Schwab U, Lemke H, Stein H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13–20.

    Article  CAS  PubMed  Google Scholar 

  7. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H . Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2: 365–371.

    Article  CAS  PubMed  Google Scholar 

  8. Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998; 153: 175–182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schwartz BR, Pinkus G, Bacus S, Toder M, Weinberg DS . Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining. Am J Pathol 1989; 134: 327–336.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Weinberg DS . The role of cell cycle activity in the generation of morphologic heterogeneity in non-Hodgkin's lymphoma. Am J Pathol 1989; 135: 759–770.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES . Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990; 14: 752–763.

    Article  CAS  PubMed  Google Scholar 

  12. Velders GA, Kluin-Nelemans JC, de BC, Hermans J, Noordijk EM, Schuuring E et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996; 14: 1269–1274.

    Article  CAS  PubMed  Google Scholar 

  13. Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E . Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11–20.

    Article  PubMed  Google Scholar 

  14. Gellert M, Mizuuchi K, O’Dea MH, Nash HA . DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976; 73: 3872–3876.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kellner U, Rudolph P, Parwaresch R . Human DNA-topoisomerases – diagnostic and therapeutic implications for cancer. Onkologie 2000; 23: 424–430.

    PubMed  Google Scholar 

  16. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P . Culprit and victim – DNA topoisomerase II. Lancet Oncol 2002; 3: 235–243.

    Article  CAS  PubMed  Google Scholar 

  17. DiNardo S, Voelkel K, Sternglanz R . DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 1984; 81: 2616–2620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Charron M, Hancock R . DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4′-dimethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside). Biochemistry 1990; 29: 9531–9537.

    Article  CAS  PubMed  Google Scholar 

  19. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997; 75: 1340–1346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21–22. Proc Natl Acad Sci USA 1988; 85: 7177–7181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hochhauser D, Stanway CA, Harris AL, Hickson ID . Cloning and characterization of the 5′-flanking region of the human topoisomerase II alpha gene. J Biol Chem 1992; 267: 18961–18965.

    CAS  PubMed  Google Scholar 

  22. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T et al. Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. J Histochem Cytochem 1997; 45: 251–263.

    Article  CAS  PubMed  Google Scholar 

  23. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999; 187: 207–216.

    Article  CAS  PubMed  Google Scholar 

  24. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de MI, Trojani M et al. Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 1999; 55: 61–71.

    Article  CAS  PubMed  Google Scholar 

  25. Provencio M, Corbacho C, Salas C, Millan I, Espana P, Bonilla F et al. The topoisomerase II alpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 1406–1411.

    CAS  PubMed  Google Scholar 

  26. Korkolopoulou P, Angelopoulou M, Siakantari M, Mitropoulos F, Vassilakopoulos T, Zorzos H et al. Evaluation of DNA topoisomerase II alpha expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001; 38: 45–53.

    Article  CAS  PubMed  Google Scholar 

  27. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR . Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995; 104: 54–59.

    Article  CAS  PubMed  Google Scholar 

  28. Brittinger G, Bartels H, Common H, Duhmke E, Fulle HH, Gunzer U et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas: results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 1984; 2: 269–306.

    Article  CAS  PubMed  Google Scholar 

  29. Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7: 365–380.

    Article  CAS  PubMed  Google Scholar 

  30. Campo E, Raffeld M, Jaffe ES . Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127.

    CAS  PubMed  Google Scholar 

  31. Weisenburger DD, Armitage JO . Mantle cell lymphoma – an entity comes of age. Blood 1996; 87: 4483–4494.

    CAS  PubMed  Google Scholar 

  32. Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.

    Google Scholar 

  33. Zucca E, Stein H, Coiffier B . European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994; 5: 507–511.

    Article  CAS  PubMed  Google Scholar 

  34. Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data [see comments]. Am J Surg Pathol 1992; 16: 637–640.

    Article  CAS  PubMed  Google Scholar 

  35. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M et al. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 1993; 142: 1689–1694.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Bankfalvi A, Riehemann K, Ofner D, Checci R, Morgan JM, Piffko J et al. Moist autoclaving. A simplified method for antigen unmasking. Pathologe 1994; 15: 345–349.

    Article  CAS  PubMed  Google Scholar 

  37. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219–229.

    Article  CAS  PubMed  Google Scholar 

  38. Kumar S, Krenacs L, Otsuki T, Kumar D, Harris CA, Wellmann A et al. bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Am J Clin Pathol 1996; 105: 737–743.

    Article  CAS  PubMed  Google Scholar 

  39. Ott MM, Helbing A, Ott G, Bartek J, Fischer L, Durr A et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol 1996; 179: 238–242.

    Article  CAS  PubMed  Google Scholar 

  40. Swerdlow SH, Yang WI, Zukerberg LR, Harris NL, Arnold A, Williams ME . Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol 1995; 26: 999–1004.

    Article  CAS  PubMed  Google Scholar 

  41. Zukerberg LR, Yang WI, Arnold A, Harris NL . Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995; 103: 756–760.

    Article  CAS  PubMed  Google Scholar 

  42. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD . Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078.

    CAS  PubMed  Google Scholar 

  43. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567–575.

    Article  CAS  PubMed  Google Scholar 

  44. Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190–196.

    Article  CAS  PubMed  Google Scholar 

  45. Andersen NS, Jensen MK, de Nully BP, Geisler CH . A Danish population-based analysis of 105 mantle cell lymphoma patients. incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002; 38: 401–408.

    Article  CAS  PubMed  Google Scholar 

  46. Hunter T, Pines J . Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582.

    Article  CAS  PubMed  Google Scholar 

  47. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 1454–1461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES . Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996; 319: 307–313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Friche E, Danks MK, Schmidt CA, Beck WT . Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 1991; 51: 4213–4218.

    CAS  PubMed  Google Scholar 

  50. Deffie AM, Batra JK, Goldenberg GJ . Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58–62.

    CAS  PubMed  Google Scholar 

  51. Davies SM, Robson CN, Davies SL, Hickson ID . Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988; 263: 17724–17729.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Department of Internal Medicine and Hematology, University Hospital of Schleswig-Holstein, Kiel, Germany

    C Schrader

  2. Division of Hematology, Department of Medicine, University of Essen, Germany

    P Meusers & G Brittinger

  3. Department of Otolaryngology, Head and Neck Surgery, Philipps University, Marburg, Germany

    A Teymoortash

  4. Department of General Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany

    J-U Siebmann

  5. Department of Pathology, University Hospital of Schleswig-Holstein, Kiel, Germany

    D Janssen

  6. Department of Hematopathology and Lymph Node Registry, German Society of Pathology, University Hospital of Schleswig-Holstein, Kiel, Germany

    R Parwaresch & M Tiemann

Authors
  1. C Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Meusers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Brittinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Teymoortash
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J-U Siebmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Parwaresch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Tiemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrader, C., Meusers, P., Brittinger, G. et al. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18, 1200–1206 (2004). https://doi.org/10.1038/sj.leu.2403387

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403387

Keywords

This article is cited by

Search

Advanced search

Quick links